35803
document
Penetration and accumulation of moxifloxacin in uterine tissue . OBJECTIVE To determine whether moxifloxacin penetrates the uterine tissue and accumulates at levels sufficient to eradicate the major pathogens causing pelvic inflammatory disease ( PID ) . METHOD In a prospective , multicenter , open-label , parallel-group study we determined the concentration of moxifloxacin in plasma and uterine tissue after a single , 400-mg intravenous dose of moxifloxacin . Study participants were randomized for time of tissue sampling , which was performed 1 , 2 , 4 , 7 , or 24 hours following the moxifloxacin infusion . RESULTS Of 43 participants , 40 were randomized to tissue sampling . Moxifloxacin accumulated in uterine tissue and concentrations were highest 1 hour after infusion in both plasma and tissue . Tissue to plasma ratios remained between 1.7 and 2.1 for 24 hours . Moxifloxacin was found to be safe and well tolerated . CONCLUSION Based on known minimum inhibitory concentration data , the uterine tissue concentrations of moxifloxacin achieved over 24 hours would be sufficient to eradicate the range of bacterial pathogens responsible for PID .
35804
Intervention_Pharmacological
moxifloxacin
35805
Intervention_Pharmacological
moxifloxacin
35806
Intervention_Pharmacological
400-mg intravenous dose of moxifloxacin
35807
Intervention_Pharmacological
moxifloxacin
35808
Outcome_Mental
Penetration and accumulation
35809
Outcome_Physical
eradicate the major pathogens
35810
Outcome_Physical
Moxifloxacin accumulated in uterine tissue and concentrations
35811
Outcome_Physical
Tissue to plasma ratios
35812
Outcome_Other
safe and well tolerated
35813
Outcome_Physical
uterine tissue concentrations
35814
Participant_Condition
pelvic inflammatory disease ( PID )
35815
Participant_Sample-size
43
35816
Participant_Sample-size
40
35817
Participant_Condition
PID